Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
Bone Marrow Transplantation
|
May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma
Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Bone Marrow Transplantation
|
October 19, 2022
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
Tarek H Mouhieddine, Erin Moshier, Santiago Thibaud, et al.
Nature Cancer
|
August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Shambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Blood Cancer Discovery
|
September 28, 2023
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, et al.
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Science Advances
|
November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Sherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Blood Advances
|
August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
Bone Marrow Transplantation
|
May 3, 2025
Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma
Darren Pan, Tarek H Mouhieddine, Tianxiang Sheng, et al.
Bone Marrow Transplantation
|
October 19, 2022
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support
Tarek H Mouhieddine, Erin Moshier, Santiago Thibaud, et al.
Nature Cancer
|
August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Shambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Blood Cancer Discovery
|
September 28, 2023
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Guido Lancman, Kian Parsa, Krzysztof Kotlarz, et al.
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Science Advances
|
November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
Sherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
JCO Precision Oncology
|
June 15, 2022
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma
Paula Restrepo, Sherry Bhalla, Yogita Ghodke-Puranik, et al.
Cancer
|
March 18, 2021
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Thomas G Martin, Nina Shah, Joshua Richter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2025
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Zachary M Avigan, Jerrel Catlett, Saoirse Bodnar, et al.
Blood Advances
|
August 26, 2022
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
Tarek H Mouhieddine, Oliver Van Oekelen, David T Melnekoff, et al.
Page
of 6